Pfizer this morning added to its methodical push into the gene therapy field, paying $51 million for a 15 percent stake in Vivet Therapeutics and the option to buy the Parisian biotech in the future.
Vivet is developing an experimental gene... Read more »
Flagship Pioneering, one of the Boston area’s top biotech company creators, has closed a new $824 million fund to help fuel the growth of its startups.
The new fund—Special Opportunities Fund II—will complement the cash the firm uses to start its... Read more »
Venture capital seems to be onboard with the fourth industrial revolution.
As the proud poster children for the tech-driven wave of change, industrial 3D printing companies have raised big dollars in the last few years, with Burlington, MA-based Desktop Metal in... Read more »
The FDA has just made brexanolone (Zulresso) the first medicine approved specifically for post-partum depression, a potentially devastating disorder that afflicts roughly one in every seven new mothers in the U.S., according to the American Psychological Association
Now the drug’s owner,... Read more »
Austin—[Updated 10:10 a.m. See below.] Magnitude Software is selling a $179 million stake in the company to London-based private equity firm 3i Group.
Chris Ney, the founder, chairman, and CEO of Magnitude, is investing alongside 3i, the company... Read more »
Flipside Crypto, a Boston startup developing analytics for cryptocurrencies, has landed its main metric onto CoinMarketCap and other financial websites including MarketWatch, TheStreet and Stocktwits, the company says.
Founded in 2017, Flipside says its Fundamental Crypto Asset Score—FCAS for short—rates the... Read more »
Houston—Tom Luby, the head of JLabs in Houston, has been named the new director of the Texas Medical Center’s Innovation Institute, the center announced Monday morning.
Luby takes over the innovation institute three months after former director Erik Halvorsen left... Read more »
While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t that long ago that another company’s gaze was fixed on the Summit, NJ, drug maker.
In the early... Read more »
There’s robotics news, clinical research companies raising cash, and plenty of early-stage venture capital money moving in the Boston technology world this week. Read on for more:
—Via Separations, a startup developing energy-efficient filtration technology, has raised $4.8 million in a... Read more »
San Antonio—Ben Kuhn has been promoted to become the CEO of Keen, a San Antonio startup that helps software developers with custom application programming interfaces for data collection and analytics.
Kuhn was hired as the general manager of Keen in... Read more »
Our annual half-day life sciences variety show, “What’s Hot in Biotech,” is back. Join Xconomy on May 21 at Bristol-Myers Squibb’s brand new offices in Kendall Square for a series of candid discussions, in a variety of formats, on... Read more »
X4 Pharmaceuticals is the latest biotech to join the public markets, but it didn’t follow the IPO path to get there.
Cambridge, MA-based X4 said Wednesday that it completed its “reverse merger” with Arsanis (NASDAQ: ASNS). Such business... Read more »
John Maraganore, CEO of Alnylam Pharmaceuticals; Penny Heaton, CEO of the Bill & Melinda Gates Medical Research Institute; digital health leader Pear Therapeutics; and renowned women-in-science advocate and MIT professor emerita Nancy Hopkins. These outstanding leaders were among the winners of... Read more »